Robert Iannone, M.D., M.S.C.E

Robert Iannone, M.D., M.S.C.E

Executive Vice President, Global Head of R&DatJazz Pharmaceuticals· In proxies 2021–2025

Pay in FY2024+14% from the year before · Jazz Pharmaceuticals stock +0.1% the same year

Robert Iannone, M.D., M.S.C.E was paid $5.7M in FY2024 (Dec), up 14%. Jazz Pharmaceuticals stock rose 0.1% that year.

Pay$100 in the stock at the end of FY20 → $75
Pay is from the Summary Compensation Table of each Jazz Pharmaceuticals proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Jazz PharmaceuticalsPublic company · 5 yr
    • Executive Vice President, Global Head of R&D2021 – Present · 5 yrStock in role +30%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?